The markets may be softening on biotech, but overall the sector remains in an incredibly strong environment.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol
Systematic Reviews Open Access 26 June 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ernst & Young. Biotech '92: Promise to Reality. Ernst & Young Annual Biotech Report. 1992 (Ernst & Young, New York, 1992).
Slud, M. Boom time for biotech. CNNMoney (22 February 2000). http://money.cnn.com/2000/02/22/companies/biotech/
Thomas, D. & Wessel, C. Emerging therapeutic company investment and deal trends (Biotechnology Industry Organization, 11 June 2015). https://www.bio.org/sites/default/files/BIO%20Emerging%20Therapeutic%20Company%20Report%20June%2011%202015.pdf
Ernst & Young. Beyond Borders: Reaching New Heights. Ernst & Young Annual Biotech Report 2015 (Ernst & Young, New York, 2015). http://www.ey.com/Publication/vwLUAssets/EY-beyond-borders-2015/$FILE/EY-beyond-borders-2015.pdf
Schulze, U. et al. Nat. Rev. Drug Discov. 13, 331–332 (2014).
Smietana, K. et al. Nat. Rev. Drug Discov. 14, 455–456 (2015).
Booth, B. et al. Improving the Pharma Research Pipeline McKinsey Quarterly, Web Exclusive August 2004 (Mckinsey, New York, 2004)
Acknowledgements
The author would like to thank his colleagues at Atlas Venture for their helpful perspectives and input into the sector, and both K. Margeson and E. Silva for data and graphical support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.L.B. participates in partnerships that invest in biotech venture capital and has a pecuniary financial interest in the success of those investments.
Rights and permissions
About this article
Cite this article
Booth, B. This time may be different. Nat Biotechnol 34, 25–30 (2016). https://doi.org/10.1038/nbt.3452
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3452
This article is cited by
-
Emerging crossover technologies: How to organize a biotechnology that becomes mainstream?
Environment Systems and Decisions (2018)
-
An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol
Systematic Reviews (2017)
-
Raising financing through strategic timing
Nature Nanotechnology (2017)